m88 sport betting app Assists Elpiscience Biopharma, Ltd. to Obtain the Exclusive Rights to Develop and Commercialize a Bispecific Antibody Drug in Greater China from TRIGR Therapeutics Inc.

In 2021, Elpiscience Biopharma, Ltd. and TRIGR m88 sport betting apprapeutics Inc. (acquired by Compass m88 sport betting apprapeutics, Inc.) announced that m88 sport betting appy had reached an agreement on m88 sport betting app exclusive development and commercialization rights of a bispecific antibody drug in Greater China.

Elpiscience Biopharma, Ltd. is a Chinese biomedical company committed to developing a new generation of innovative drugs for tumor immunom88 sport betting apprapy. TRIGR is an American biomedical company focusing on m88 sport betting app treatment of tumors with anti-angiogenesis and immunomodulation.

m88 sport betting app was entrusted by Elpiscience Biopharma, Ltd. to draft the license agreement in the project, and led the subsequent negotiation and modification of the agreement. m88 sport betting app provided the project with high-quality, rigorous and efficient professional legal services during the whole transaction process, which has been highly praised by the clients.

This project was led by Ph. D. Wang, Zhaohui (Zoe), m88 sport betting app it was managed by Partner Mr. Zhao, Hao (Gerry).